<table>
<thead>
<tr>
<th>Test</th>
<th>Description</th>
<th>Validated endpoint(s) in a biopsy setting</th>
<th>Biomarker selection specific for prostate cancer</th>
<th>Patient’s Specimen</th>
<th>Patient Access</th>
</tr>
</thead>
</table>
| **oncotype DX**<sup>®</sup>  | **Genomic Prostate Score™:** Predicts the likelihood of Prostate Cancer Death and Metastasis within 10 years after RP, and Adverse Pathology<sup>1</sup> using multiple genomic pathways | - Adverse Pathology  
- Biochemical Recurrence, Prostate Cancer Death and Metastasis within 10 years after RP  
- High Grade Disease  
- Non-Organ Confined Disease | YES                                        | Positive Biopsy  
NCCN<sup>®</sup> Very Low, Low, Favorable-Intermediate risk GS 3+3, 3+4 | Medicare Reimbursed for biopsy NCCN Very Low<sup>†</sup>/Low<sup>‡</sup> and Favorable Intermediate<sup>§</sup>  
Financial Assistance Available |
| **Prolaris®**<sup>®</sup>     | **Cell Cycle Progression Score:** Reports the risk of dying from untreated disease in ten years, using a single genomic pathway | - 10-year Untreated Mortality  
- Biochemical Recurrence  
- Metastasis after RP | NO                                          | Positive Biopsy  
AUA<sup>®</sup> Low-High Risk | Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate  
Financial Assistance Available |
| **Decipher®**<sup>®</sup>     | **Genomic Classifier:** Predicts the probability of metastasis after surgery or radiation using multiple genomic pathways | - High Grade Disease  
- 10-year Metastasis after RP  
- Metastasis after radiation therapy | YES                                        | Positive Biopsy  
NCCN Low-High Risk | Medicare Reimbursed in Post RP Only  
Financial Assistance Available |
| **ProMark®**<sup>®</sup>      | **ProMark Score:** Predicts likelihood of Adverse Pathology using protein staining | - Adverse Pathology  
- High Grade Disease  
- Non-Organ Confined Disease | YES                                        | Positive Biopsy  
GS 3+3, 3+4 | Medicare Reimbursed for biopsy NCCN Very Low/Low  
Financial Assistance Available |
| **ConfirmMDx®**<sup>®</sup>   | **ConfirmMDx result:** Predicts likelihood of negative repeat biopsy | Negative Repeat Biopsy | YES                                        | Negative Biopsy  
HGPIN Biopsy | Medicare Reimbursed  
Financial Assistance Available |
| **4KScore®**<sup>®</sup>      | **4KScore:** Provides probability of aggressive cancer on initial biopsy | Likelihood of GS 3+4 and higher at initial biopsy | YES                                        | Blood Biopsy eligible patients | Financial Assistance is not reported on website |

"Men with clinically localized disease may consider the use of tumor-based molecular assays. Retrospective case cohort studies have shown that the molecular assays performed on biopsy or prostatectomy specimens provide prognostic information independent of NCCN risk groups."

<sup>1</sup>Gleason 3+3=6 (GG1):  
- PSA<20  
- <cT1c-cT2a  
<sup>2</sup>Gleason 3+3=6 (GG1):  
- PSA<10  
- <cT2b-cT2c  
<sup>3</sup>Gleason 3+4+7 (GG2):  
- PSA<10  
- cT1c-cT2a

Genomic Health, Oncotype DX and Oncotype DX Genomic Prostate Score are registered trademarks of Genomic Health, Inc. ©2018 Genomic Health, Inc. All rights reserved. All other trademarks are the properties of their respective owners. GHI40151_0118